

# Erratum

Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM: Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. *Diabetes Care* 30:1351–1356, 2007

In Table 2 of the above-listed article, column headings for “Telmisartan” and “Ramipril” were incorrectly placed. The correct table appears below.

Table 2—Effects of 80 mg telmisartan and 10 mg ramipril on secondary renal end points and MAP

Parameter*	Telmisartan			Ramipril		
	Before treatment	After treatment	<i>P</i> value	Before treatment	After treatment	<i>P</i> value
RPF (ml/min)	652 ± 27.0	696 ± 31.0	0.047	631 ± 27.3	658 ± 28.2	0.221
GFR (ml/min)	136.3 ± 3.1	136.4 ± 3.4	0.212	134.3 ± 3.7	133.7 ± 3.8	0.558
Filtration fraction (%)	22.0 ± 0.8	20.6 ± 0.7	0.020	22.2 ± 0.7	21.4 ± 0.7	0.154
MAP (mmHg)	100.0 ± 10.4	93.3 ± 10.8	<0.001	100.1 ± 9.2	95.4 ± 11.0	0.009
Renal vascular resistance (RU)	96.2 ± 4.2	87.1 ± 4.2	0.010	99.3 ± 4.7	93.7 ± 5.1	0.119

Data are means ± SE. \*No significant differences in the changes due to treatment were observed between telmisartan and ramipril. RU, resistance unit.